secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alaunos Therapeutics, Inc. (TCRT)
CIK:        0001107421
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001193125-23-276662
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alaunos receives Nasdaq delisting notice; Q3 net loss $8.5M; exploring strategic alternatives
--------------------------------------------------------------------------------

- Nasdaq determined to delist TCRT because bid price was below $0.10 for 10 consecutive days; suspension effective Nov 17, 2023.
- Company intends to appeal to a Nasdaq Hearings Panel; trading stays pending appeal.
- Q3 2023 net loss $8.5M ($0.04 per share); revenue $0 vs $2.9M a year ago.
- Cash and equivalents $11.9M; cost-savings expected to extend runway into Q2 2024.
- TCR-T Phase 1/2 trial showed 87% disease control rate in 8 patients; company halted further development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1107421/000119312523276662/0001193125-23-276662-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1107421/000119312523276662/d349273d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-276662

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer